Call Options

25 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $3.99 Million - $5.08 Million
9,200 Added 11.81%
87,100 $47.2 Million
Q2 2024

Aug 15, 2024

SELL
$356.01 - $451.55 $13.4 Million - $17 Million
-37,600 Reduced 32.55%
77,900 $33.5 Million
Q1 2024

May 07, 2024

SELL
$356.95 - $413.29 $29 Million - $33.6 Million
-81,200 Reduced 41.28%
115,500 $45.5 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $16.4 Million - $24.5 Million
48,500 Added 32.73%
196,700 $74.8 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $3.36 Million - $4.99 Million
9,100 Added 6.54%
148,200 $72.9 Million
Q2 2023

Aug 11, 2023

BUY
$360.14 - $422.58 $33.8 Million - $39.7 Million
93,900 Added 207.74%
139,100 $54.2 Million
Q1 2023

May 16, 2023

SELL
$334.23 - $403.65 $11.1 Million - $13.4 Million
-33,100 Reduced 42.27%
45,200 $16.8 Million
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $9.41 Million - $11.1 Million
27,500 Added 54.13%
78,300 $29.7 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $2.88 Million - $3.32 Million
-8,400 Reduced 14.19%
50,800 $17.9 Million
Q2 2022

Aug 15, 2022

BUY
$269.58 - $378.88 $4.26 Million - $5.99 Million
15,800 Added 36.41%
59,200 $22.4 Million
Q1 2022

May 16, 2022

SELL
$254.45 - $351.06 $2.21 Million - $3.05 Million
-8,700 Reduced 16.7%
43,400 $13.7 Million
Q4 2021

Feb 14, 2022

SELL
$272.01 - $353.03 $1.96 Million - $2.54 Million
-7,200 Reduced 12.14%
52,100 $18.2 Million
Q3 2021

Nov 15, 2021

SELL
$295.0 - $350.58 $4.48 Million - $5.33 Million
-15,200 Reduced 20.4%
59,300 $17.9 Million
Q2 2021

Aug 11, 2021

BUY
$257.11 - $319.92 $3.37 Million - $4.19 Million
13,100 Added 21.34%
74,500 $22.4 Million
Q1 2021

May 17, 2021

BUY
$268.3 - $380.31 $429,280 - $608,496
1,600 Added 2.68%
61,400 $16.9 Million
Q4 2020

Feb 16, 2021

SELL
$248.13 - $308.36 $7.94 Million - $9.87 Million
-32,000 Reduced 34.86%
59,800 $17.6 Million
Q3 2020

Nov 16, 2020

SELL
$215.51 - $272.51 $6.49 Million - $8.2 Million
-30,100 Reduced 24.69%
91,800 $24.1 Million
Q2 2020

Aug 14, 2020

SELL
$127.44 - $232.72 $8.87 Million - $16.2 Million
-69,600 Reduced 36.34%
121,900 $27.5 Million
Q1 2020

May 15, 2020

BUY
$108.83 - $165.23 $15.4 Million - $23.4 Million
141,700 Added 284.54%
191,500 $25.2 Million
Q4 2019

Feb 14, 2020

SELL
$106.59 - $164.21 $852,720 - $1.31 Million
-8,000 Reduced 13.84%
49,800 $7.99 Million
Q3 2019

Nov 14, 2019

BUY
$113.31 - $150.51 $2.45 Million - $3.25 Million
21,600 Added 59.67%
57,800 $6.59 Million
Q2 2019

Aug 14, 2019

BUY
$115.0 - $141.58 $3.46 Million - $4.26 Million
30,100 Added 493.44%
36,200 $5.13 Million
Q1 2019

May 15, 2019

SELL
$98.85 - $134.59 $563,445 - $767,163
-5,700 Reduced 48.31%
6,100 $762,000
Q4 2018

Feb 14, 2019

SELL
$63.81 - $109.82 $1.58 Million - $2.71 Million
-24,700 Reduced 67.67%
11,800 $1.13 Million
Q3 2018

Nov 14, 2018

BUY
$75.5 - $96.63 $2.76 Million - $3.53 Million
36,500 New
36,500 $2.77 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.